 framed systematic evidence reviews. The quantity and quality of evidence available was also an
important factor in determining the rationale for the systematic
review topics. De novo evidence reviews were undertaken to
examine the rationale for screening in asymptomatic PAD
and the comparative effectiveness of current treatments for
IC. These systematic reviews are published jointly with this
guideline document.1,2
The committee developed the practice guideline by
assigning two or three members to create primary drafts of
each section of the